[12] Metformin: Anchor in the GLP-1 RA Care Continuum Journey The mechanistic, real-world, clinical trials and pharmacovigilance evidence landscape suggests metformin as the potential anchor pharmacological agent across the entire GLP-1 RA care continuum, during therapy and beyond.Table 1 summarises the key potential outcome benefits at each phase
Long chain (LC)-acylcarnitines profile
It is important to distinguish between pain directly caused by the medication and pain that may arise indirectly through physiological changes associated with treatmentsuch as weight loss, altered body composition, or changes in physical activity levels
With flexible online care and brand-name medications, its a strong option for those seeking reliable weight-loss support
Patients who reach 2.4 mg with manageable side effects are positioned for the longest part of the weight loss curve, which spans the next several months at the maintenance dose
Only about 25% of patients experience significant nausea